Hormonal
Sibutramine increases the risk of nonfatal cardiovascular events (myocardial infarction and stroke) in patients with pre-existing cardiovascular disease or type 2 diabetes with additional risk factors, leading to its contraindication in these populations.
If you have heart disease, a history of stroke, or diabetes combined with other heart risks (like high blood pressure or smoking), sibutramine is not safe for you. It increases your chance of having a heart attack or stroke. Do not use this medication if you fall into these categories; consult your doctor for safer alternatives.
In patients treated with sibutramine, the risk rate of cardiovascular events increased by 16%, with the risk of nonfatal acute myocardial infarction (AMI) increasing by 28% and the risk of nonfatal stroke increasing by 36%. Thus, sibutramine was associated with an increased risk of nonfatal cardiovascular events in this group of patients.
Why this rating
Based on the SCOUT study, a large, long-duration, high-quality RCT.
Source
Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM)
Rodrigo O. Moreira et al. · Archives of Endocrinology and Metabolism · 2024
DOI 10.20945/2359-4292-2024-0422
More from this paper
- Liraglutide 3.0 mg, a GLP-1 analogue, promotes weight loss and improves metabolic parameters through mechanisms involving hypothalamic energy balance regulation, glucose-dependent insulin stimulation, and slowed gastric emptying.Strong
- Orlistat reduces the incidence of type 2 diabetes in individuals with prediabetes or impaired glucose tolerance by approximately 37% over four years compared to placebo when combined with lifestyle changes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →